by Brad N. Taylor, Ph.D. | Aug 9, 2022
The key to every successful therapy is consistency. Cell therapy manufacturers need solutions that allow them to efficiently harness the ability of a living cell to respond to its environment, while simultaneously delivering replicable and consistent quality...
by Brad N. Taylor, Ph.D. | Feb 8, 2022
Age-related macular degeneration (AMD) is the degeneration/dysregulation of cells of the retinal pigment epithelium (RPE) and is the most common cause of severe loss of central vision among people 50 and older, affecting approximately 200 million people worldwide [1]....
by Brad N. Taylor, Ph.D. | Jan 18, 2022
Getting Attached In the final part of this 3-part blog series, Defining the undefined with Vitronectin XF™, get attached to Vitronectin even more as we delve into the performance data. In our previous blogs, we discussed how mixed extracellular matrix (ECM) gels such...
by Brad N. Taylor, Ph.D. | Jan 11, 2022
Clearing the Regulatory Hurdles Defined single component ECM gels have distinct advantages for stem cell therapies, improving patient safety and accelerating regulatory approval. Last week, we looked at the evolution in cell culture for mesenchymal (MSC) and induced...
by Brad N. Taylor, Ph.D. | Jan 4, 2022
Bringing Standardization to Stem Cell Process Development. A recombinant cell attachment factor brings standardization to stem cell production. Over the last few decades, human embryonic stem cells (hESCs) and subsequently induced pluripotent stem cells (iPSCs) have...
